0001156175-14-000011.txt : 20140212
0001156175-14-000011.hdr.sgml : 20140212
20140212171519
ACCESSION NUMBER: 0001156175-14-000011
CONFORMED SUBMISSION TYPE: SC 13G/A
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20140212
DATE AS OF CHANGE: 20140212
GROUP MEMBERS: BROOKSIDE CAPITAL TRADING FUND, L.P.
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: IDENIX PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001093649
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 450478605
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: SC 13G/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 005-79969
FILM NUMBER: 14601384
BUSINESS ADDRESS:
STREET 1: 320 BENT STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
BUSINESS PHONE: 617-995-9800
MAIL ADDRESS:
STREET 1: 320 BENT STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
FORMER COMPANY:
FORMER CONFORMED NAME: NOVIRIO PHARMACEUTICALS LTD
DATE OF NAME CHANGE: 19990820
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: BROOKSIDE CAPITAL MANAGEMENT LLC
CENTRAL INDEX KEY: 0001156175
IRS NUMBER: 043517087
STATE OF INCORPORATION: DE
FILING VALUES:
FORM TYPE: SC 13G/A
BUSINESS ADDRESS:
STREET 1: JOHN HANCOCK TOWER
STREET 2: 200 CLARENDON STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 617-516-2000
MAIL ADDRESS:
STREET 1: JOHN HANCOCK TOWER
STREET 2: 200 CLARENDON STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
SC 13G/A
1
IdenixSC13G.txt
BROOKSIDE 13G FOR IDENIX PHARMACEUTICALS, INC. AS OF DECEMBER 31, 2013
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
(Rule 13d-102)
Information Statement Pursuant to Rules 13d-1 and 13d-2
Under the Securities Exchange Act of 1934
(Amendment No. 4)*
Idenix Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, Par Value $0.001
(Title of Class of Securities)
45166R204
(CUSIP Number)
December 31, 2013
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which
this schedule is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting
persons initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be filed for the purpose of Section 18 of the Securities Exchange
Act of 1934 (Act) or otherwise subject to the liabilities of that section
of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).
CUSIP No. 45166R204
13G/A
Page 2 of 5 Pages
1.
NAME OF REPORTING PERSON
Brookside Capital Trading Fund, L.P.
2.
(a)
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(b)
3.
SEC USE ONLY
4.
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.
SOLE VOTING POWER
13,115,858 Shares
6.
SHARED VOTING POWER
0
7.
SOLE DISPOSITIVE POWER
13,115,858 Shares
8.
SHARED DISPOSITIVE POWER
0
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
13,115,858 Shares
10.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES
11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.79%
12.
TYPE OF REPORTING PERSON
PN
Item 1(a). Name of Issuer
The name of the issuer to which this filing on Schedule 13G/A
relates is Idenix Pharmaceuticals, Inc. (the Company).
Item 1(b). Address of Issuers Principal Executive Offices
The principal executive offices of the Company are located at
320 Bent Street, Cambridge, MA 02141.
Item 2(a). Name of Person Filing
This Statement is being filed on behalf of Brookside Capital Trading
Fund, L.P., a Delaware limited partnership (Trading Fund), whose sole
general partner is Brookside Capital Investors II, L.P., a Delaware
limited partnership (Brookside Investors II), whose sole general
partner is Brookside Capital Management, LLC, a
Delaware limited liability company (Brookside Management).
Item 2(b). Address of Principal Business Office or, if none, Residence
The principal business address of each of Trading Fund, Brookside
Investors II, and Brookside Management is John Hancock Tower, 200
Clarendon Street, Boston, MA 02116.
Item 2(c). Citizenship
Each of the Trading Fund, Brookside Investors II and Brookside
Management is organized under the laws of the State of Delaware.
Item 2(d). Title of Class of Securities
The class of equity securities of the Company to which this
filing on Schedule
13G/A relates is Common Stock, Par Value $0.001 (Common Stock).
Item 2(e). CUSIP Number
The CUSIP number of the Companys Common Stock is 45166R204.
Item 3. If this statement is filed pursuant to 240.13d-1(b) or
240.13d-2(b) or (c), check whether the person filing is a:
(a) [ ] Broker or dealer registered under section 15 of the
Act (15 U.S.C. 78o).
(b) [ ] Bank as defined in section 3(a)(6) of the
Act (15 U.S.C. 73c).
(c) [ ] Insurance company as defined in section 3(a)(19) of the
Act (15 U.S.C. 78c).
(d) [ ] Investment company registered under section 8 of the
Investment Company Act of 1940 (15 U.S.C. 80a-8).
(e) [ ] An investment adviser in accordance with 13d-1(b)(1)(ii)(E).
(f) [ ] An employee benefit plan or endowment fund in accordance with
240.13d-1(b)(1)(ii)(F).
(g) [ ] A parent holding company or control person in accordance with
240.13d-1(b)(1)(ii)(G).
(h) [ ] A savings association as defined in Section 3(b) of the Federal
Deposit Insurance Act (12 U.S.C. 1813).
(i) [ ] A church plan that is excluded from the definition of an
investment company
under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
(j) [ ] Group, in accordance with 240.13d-1(b)(1)(ii)(J).
[x] If this statement is filed pursuant to 240.13d-1(c), check
this box.
Item 4. Ownership
Item 4(a). Amount beneficially owned
As of the close of business on December 31, 2013, the Trading
Fund beneficially
owned 13,115,858 shares of the Common Stock of the Company.
Item 4(b). Percent of Class
As of the close of business on December 31, 2013, the Trading Fund
was the beneficial owner of 9.79% of the Common Stock of the Company.
The percentage of Common Stock reported owned by the Trading Fund is
based upon 134,000,750 shares of Common Stock outstanding, which is the
total number of shares of Common Stock outstanding as of October 18,
2013, based on representations made in the Companys 10Q filed with the
Securities and Exchange Commission on October 30, 2013.
Item 4(c). Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: 13,115,858 Shares
(ii) shared power to vote or to direct the vote: 0
(iii) sole power to dispose or to direct the
disposition of: 13,115,858 Shares
(iv) shared power to dispose or to direct the
disposition of: 0
Item 5. Ownership of Five Percent or Less of a Class
Not Applicable.
Item 6. Ownership of More than Five Percent on Behalf of Another Person
Not Applicable.
Item 7. Identification and Classification of the Subsidiary which
Acquired the Security
Being Reported on by the Parent Holding Company:
Not Applicable.
Item 8. Identification and Classification of Members of the Group
Not Applicable.
Item 9. Notice of Dissolution of Group
Not Applicable.
Item 10. Certification
By signing below, the undersigned certifies that, to the best of its
knowledge and belief, the securities referred to above were not acquired
and are not held for the purpose of or with the effect of changing or
influencing the control of the issuer of the securities and were not
acquired and are not held in connection with or as a participant in any
transaction having that purpose or effect.
Dated: February 12, 2014
After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true,
complete, and correct.
BROOKSIDE CAPITAL TRADING FUND, L.P.
By: Brookside Capital Investors II, L.P.,
its general partner
By: Brookside Capital Management, LLC,
its general partner
By: /s/ William E. Pappendick IV
Name: William E. Pappendick IV
Title: Managing Director